newsfilter
← Latest News
GlobeNewswire·

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel